Isis Pharmaceuticals has reportedly closed down Altair Therapeutics, which it had spun off in 2007 to develop AIR645, an inhaled IL-4 and IL-13 inhibitor for the treatment of asthma. The drug, which was the only one in Altair’s pipeline, failed its latest trial in the fall of 2010. Altair had seven employees. Read an article.
Altair Therapeutics is no more
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
